The leading cause of preventable combat death is uncontrolled bleeding. A Korean lab says its new powder can stop it in one second.

Uncontrolled hemorrhage is the leading cause of preventable death on the battlefield, and the conventional tools used to stop it were designed for flat, accessible wounds. Patches and gauzes need a surface to press against. Deep, irregular, and junctional wounds, the ones that bleed fastest and sit closest to major vessels, are exactly where those tools cannot get purchase. That structural mismatch has been a known gap in combat medicine for years. It is the gap a team at the Korea Advanced Institute of Science and Technology (KAIST) now says its new spray-on powder is built to close.

The product, reported in Advanced Functional Materials, is a dry powder that gels into a physical barrier within roughly one second of contact with blood. The trigger is chemistry the wound already contains: calcium and other positively charged ions circulating in blood react with two of the powder's three ingredients, alginate and gellan gum, to lock the material into a solid seal. A third ingredient, chitosan, then bonds with blood components to reinforce the clot chemically. Together, the KAIST team writes, the powder forms a conformal plug that fills whatever cavity it lands in, rather than lying on top of a surface.

The numbers the team reported in animal and lab tests make the design intent concrete. The gelled powder absorbs more than seven times its own weight in blood, and its adhesive strength to surrounding tissue exceeds 40 kilopascals, which the KAIST News Center describes as strong enough to withstand firm hand pressure. In a surgical liver-injury model, the powder outperformed existing commercial hemostatic agents. Hemolysis stayed under 3 percent, cell viability held above 99 percent, and an antibacterial assay reported 99.9 percent effectiveness. Liver function in treated animals returned to normal within two weeks of surgery, with no observed systemic toxicity.

Those figures come with a caveat the headline number does not. The roughly one-second gel time is a result measured in vitro and in animal models, not in human trauma patients. The paper, covered by ScienceDaily and SciTechDaily, describes a research-stage material, not a deployed medical product. There is no public data on human hemostasis time, no clinical trial enrollment, and no regulatory milestone in the public KAIST materials or the journal article for this formulation.

Storage stability is part of why the Army is in the room. The powder kept its hemostatic performance through two years at room temperature and high humidity, according to the KAIST announcement, a property aimed at stockpiles that sit in vehicles and field kits rather than climate-controlled pharmacies. The Army co-researcher's role signals that the powder was engineered to survive field conditions, not idealized lab ones. The team frames the material as dual-use, with civilian emergency medicine, disaster response, and low-resource clinics as plausible downstream beneficiaries.

The work was led by Professor Steve Park of KAIST's Department of Materials Science and Engineering and Professor Sangyong Jon of the Department of Biological Sciences, with an Army major as a co-researcher on a paper titled "An Ionic Gelation Powder for Ultrafast Hemostasis and Accelerated Wound Healing." The Medical Xpress summary notes the materials are all naturally derived and biocompatible, which the team says supports the safety profile but does not by itself clear a regulatory path.

The next question is whether the mechanism holds up in human wounds under field conditions, and whether the same calcium-triggered gelation behaves the same way in the presence of hypothermic, coagulopathic, or heavily contaminated blood. That is the gap between a materials-science result and a medic's tool, and it is the line the work has not yet crossed.